[{"orgOrder":0,"company":"Therabest","sponsor":"Glycotope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"GT-00AxIL15","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therabest","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Therabest \/ Glycotope","highestDevelopmentStatusID":"4","companyTruncated":"Therabest \/ Glycotope"}]

Find Clinical Drug Pipeline Developments & Deals by Therabest

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform improves the activity of TB-100.

                          Brand Name : TB-100

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 13, 2022

                          Lead Product(s) : TB-100,GT-00AxIL15

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Glycotope

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank